A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection
PLoS ONE2013Vol. 8(5), pp. e63818–e63818
Citations Over TimeTop 10% of 2013 papers
David Gardiner, Jay Lalezari, Eric Lawitz, Michael A. DiMicco, R. Ghalib, K. Rajender Reddy, Kyong‐Mi Chang, Mark Sulkowski, Steven O’ Marro, Jeffrey Anderson, Bing He, Vikram Kansra, Fiona McPhee, Megan Wind‐Rotolo, Dennis M. Grasela, M. J. Selby, Alan J. Korman, Israel Lowy
Abstract
ClinicalTrials.gov NCT00703469.
Related Papers
- → A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia(2002)434 cited
- → Altered Placebo and Drug Labeling Changes the Outcome of Episodic Migraine Attacks(2014)391 cited
- → Gender Differences in Placebo Analgesia: Event-Related Potentials and Emotional Modulation(2011)116 cited
- → Conditioned Placebo Analgesia Persists When Subjects Know They Are Receiving a Placebo(2015)116 cited
- → Μελέτη της πολυπαραγοντικής αναλγησίας στο μετεγχειρητικό πόνο μετά από λαπαροσκοπική χολοκυστεκτομή(2014)